{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-084861","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-07-20T11:13:05+00:00","discovered_at":"2026-07-20T11:15:00.254350+00:00","generated_at":"2026-07-20T11:15:21.948387+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Armata Pharmaceuticals Reports Progress on AP-SA02 Phase 3 Study and Promotes David House to CFO","bullets":["Submitted complete Phase 3 superiority protocol to FDA for AP-SA02, addressing all End-of-Phase 2 meeting comments.","Completed four engineering runs of AP-SA02 at cGMP facility; clinical trial material production is next step.","Received $2.5 million continuation award from DoD, bringing total funding to $28.7 million for Phase 3 readiness.","Promoted David House to Chief Financial Officer; he previously served as SVP, Finance since August 2024.","Phase 3 superiority study remains on track to initiate in the second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-084861","json":"https://secwatch.observer/filing/0001104659-26-084861.json","markdown":"https://secwatch.observer/filing/0001104659-26-084861.md","text":"https://secwatch.observer/filing/0001104659-26-084861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/0001104659-26-084861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/tm2620782d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T11:15:21.948387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}